Comparison · NCT00772031-f18731bc
Topiramate Plus Proporanolol vs Topiramate Plus Placebo: Number of Subjects Experiencing at Least a 30% Reduction in 28-day Moderate to Severe Headache Days
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Topiramate Plus Proporanolol vs Topiramate Plus Placebo: Number of Subjects Experiencing at Least a 30% Reduction in 28-day Moderate to Severe Headache Days. Trial comparisons, record NCT00772031-f18731bc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00772031-f18731bc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.44 | 0.339 | 0.547 | wilson | |
| Risk in group 2 | 0.341 | 0.248 | 0.449 | wilson | |
| Risk difference, group 1 minus group 2 | 0.099 | -0.0488 | 0.241 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.29 | 0.878 | 1.9 | log | |
| Odds ratio, group 1 over group 2 | 1.52 | 0.811 | 2.84 | log | |
| Number needed to treat, for one more participant with the outcome on Topiramate Plus Proporanolol than on Topiramate Plus Placebo | 10.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Topiramate Plus Proporanolol | Participants will receive propranolol and topiramate. | 37 | 84 | OG000 |
| Group 2 | Topiramate Plus Placebo | Participants will receive placebo and topiramate. | 28 | 82 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects Experiencing at Least a 30% Reduction in 28-day Moderate to Severe Headache Days
- Description
- Time frame
- 6 months post randomization
- Population
All subjects randomized with opportunity for 6 month followup. Due to early study termination those who did not have opportunity for 6 month followup at time of study closure were excluded. All lost to followups were counted as failure
Source ClinicalTrials.gov
Trial
- Title
- NINDS CRC Chronic Migraine Treatment Trial
- NCT number
- NCT00772031
- Phases
- PHASE3
- Conditions
- Chronic Migraine
- Interventions
- propranolol LA, topiramate, placebo
- Lead sponsor
- Anne Lindblad
- Results first posted
- 2012-01-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00772031?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00772031-f18731bc